The pharmaceutical giant is teaming up with Verily Life Sciences to form Galvani Bioelectronics. GlaxoSmithKline has announced plans to create a new company with the life sciences unit of Google-owner Alphabet in a bid to expand the use of electric signals to fight diseases. Collectively, the two companies plan to invest a total of £540 million over seven years. In the UK 30 scientists, engineers and clinicians will… GSK will own 55 per cent of the new company, which will be primarily based at its research and development centre in Stevenage, while Verily will own the remaining 45 per cent.

Source: The Times August 01, 2016 07:52 UTC